Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Integrated multi-omics reveal lactate metabolism-related gene signatures and PYGL in predicting HNSCC prognosis and immunotherapy efficacy

Fig. 2

Construction of LMRGs prognostic model and survival analysis. (A) The Venn diagram shows the intersection between LMRGs and DEGs. (B) The heatmap depicts the relative expression of 23 genes involved in lactate metabolic activities that were shown to vary between tumor and normal specimens. (C-E) In the TCGA, GEO, and FJZL cohorts, low-risk group patients had a favorable OS rate as opposed to those in the high-risk group. (F) The ROC curve for HNSCC patients’ OS over 1, 3, and 5 years in the TCGA, GEO, and FJZL cohorts. (G) Construction of a nomogram based on riskscore and clinical characteristics. (H) Calibration curves of the nomogram for predicting OS in TCGA-HNSCC patients. (I) Correlation analysis of clinical features and risk score

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us